Reference is made to the stock exchange announcement published by Observe
Medical ASA (the "Company") on 27 November 2023 regarding the allocation of
subscription rights (the "Subscription Rights") in the rights issue ("Rights
Issue") to primary insiders and close associates.

Per Arne Nygård, CFO in the Company, has exercised 450,000 Subscription Rights,
entitling Per Arne Nygård to be allocated 450,000 offer shares in the Rights
Issue at a price per offer share of NOK 0.26, subject to the Rights Issue being
completed. For more information see the attached mandatory notification of
trade.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.

For further information about the Company, please contact:

Rune Nystad, CEO Observe Medical

Mobile: +47 916 24 683

E-mail: rune.nystad@observemedical.com

Per Arne Nygård, CFO Observe Medical

Mobile: +47 411 04 345

E-mail: perarne.nygard@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care,
in combination with targeted M&A.

The Company is headquartered in Oslo, Norway, with additional offices in Narvik,
Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US. In
addition, Observe Medical has a direct sale organization in the Nordics and a
distributor network internationally.

Further information is available at www.observemedical.com.